Korbelik M, Naraparaju V R, Yamamoto N
Cancer Imaging, British Columbia Cancer Agency, Vancouver, Canada.
Br J Cancer. 1997;75(2):202-7. doi: 10.1038/bjc.1997.34.
The effect of Photofrin-based photodynamic therapy (PDT) and adjuvant treatment with serum vitamin D3-binding protein-derived macrophage-activating factor (DBPMAF) was examined using a mouse SCCVII tumour model (squamous cell carcinoma). The results show that DBPMAF can markedly enhance the curative effect of PDT. The most effective DBPMAF therapy consisted of a combination of intraperitoneal and peritumoral injections (50 and 0.5 ng kg-1 respectively) administered on days 0, 4, 8 and 12 after PDT. Used with a PDT treatment curative to 25% of the treated tumours, this DBPMAF regimen boosted the cures to 100%. The DBPMAF therapy alone showed no notable effect on the growth of SCCVII tumour. The PDT-induced immunosuppression, assessed by the evaluation of delayed-type contact hypersensitivity response in treated mice, was greatly reduced with the combined DBPMAF treatment. These observations suggest that the activation of macrophages in PDT-treated mice by adjuvant immunotherapy has a synergistic effect on tumour cures. As PDT not only reduces tumour burden but also induces inflammation, it is proposed that recruitment of the activated macrophages to the inflamed tumour lesions is the major factor for the complete eradication of tumours.
利用小鼠SCCVII肿瘤模型（鳞状细胞癌）研究了基于卟吩姆钠的光动力疗法（PDT）以及血清维生素D3结合蛋白衍生的巨噬细胞激活因子（DBPMAF）辅助治疗的效果。结果表明，DBPMAF可显著增强PDT的疗效。最有效的DBPMAF治疗方案是在PDT后第0、4、8和12天分别进行腹腔注射和瘤周注射（分别为50和0.5 ng kg-1）。将该DBPMAF方案与对25%的治疗肿瘤有效的PDT治疗联合使用时，治愈率提高到了100%。单独使用DBPMAF治疗对SCCVII肿瘤的生长没有显著影响。通过评估治疗小鼠的迟发型接触超敏反应来评估，联合DBPMAF治疗可大大降低PDT诱导的免疫抑制。这些观察结果表明，辅助免疫疗法激活PDT治疗小鼠中的巨噬细胞对肿瘤治愈具有协同作用。由于PDT不仅可减轻肿瘤负荷，还可诱导炎症，因此有人提出，将活化的巨噬细胞募集到炎症性肿瘤病变是肿瘤完全根除的主要因素。
